Developer docs
API playgroundTry for free, no card

Search company profiles

Allos

Full company profile

uuid0008k4m

Namestring
Allos
Legal namestring
Allos AI
Websiteurl
allos.ai
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Allos AI is an Oxford University spinout that has built a causal AI platform targeted at pharmaceutical R&D, specifically formulation development for complex generics and small-molecule medicines for chronic conditions. The company's core technology combines causal inference with simulation-led Design of Experiments (DoE) and a closed-loop learning system to model cause-and-effect relationships between process interventions and outcomes before physical experiments are run. The platform is modularized into four product areas — Formulation Development, Scale-Up, Tech Transfer & QA, and Clinical Trials — each addressing a distinct phase of the molecule-to-validated-process workflow.

The product ingests structured experimental, process, and real-world data to perform phase-space mapping, identify robust operating windows, quantify sensitivities, and stratify patients. Disclosed validated outcomes include a 30% reduction in non-response rates to biologic therapies, 50% lower inter-patient variability, and 70% fewer scale-up and tech-transfer failures. The company positions its offering as the industry's first "glass-box" causal AI platform, contrasting its explainability with conventional black-box predictive models used in pharma R&D.

Commercially, Allos operates an enterprise direct-sales motion aimed at pharmaceutical sponsors, supported by a quote-based engagement model with no publicly disclosed pricing. Revenue mechanics span subscription/recurring AI platform services alongside professional services for formulation development. The company is headquartered in Oxford, United Kingdom, employs between 11 and 50 people, and was recently capitalized with a $5 million seed round led by Oxford Science Enterprises, with participation from Habico Invest (the family office of Danish pharma group Orifarm) and Berkeley SkyDeck. Note: a firmographic short description characterizes Allos as serving autoimmune prognosis/monitoring/treatment; the overwhelming majority of source material instead describes pharmaceutical formulation and R&D, which is the positioning used here.

Short descriptiontext

Allos AI is an Oxford University spinout selling a causal AI platform to pharmaceutical sponsors for formulation development, scale-up, tech transfer, and clinical trial optimization in specialty generics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBerkeley, United States
HQ citystring
Berkeley
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
causal AI platform, pharmaceutical R&D, formulation development, clinical trial optimization, drug development AI
Industry2 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Computer Systems Design and Related Services54151
SIC code3 codes
  • Services-Prepackaged Software7372
  • Services-Commercial Physical & Biological Research8731
  • Services-Computer Programming Services7371
Product category
Pharmaceutical R&D AI Software
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1AI Platform Services
TypeSubscription Recurring
Description

Providing causal AI platform services for formulation development, scale-up, tech transfer, QA, and clinical trials to pharmaceutical sponsors.

dcatvci.org
2Formulation Development Services
TypeProfessional Services
Description

AI-powered formulation development services including phase-space mapping and simulation-led DoE for pharmaceutical companies.

allos.ai
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Allos develops and sells a Causal AI platform for pharmaceutical development that simulates how interventions affect outcomes, defining robust operating windows before experiments run. The platform combines integrated modules for formulation development, scale-up, tech transfer/QA, and clinical trials, learning from every run and deviation to serve as a single source of truth with traceable drivers. The company sells both the AI platform (subscription-based) and formulation development services to pharmaceutical sponsors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 30% reduction in non-response rates to biologic therapies
+2 more records
Product overview1 text field

Allos offers a unified AI platform (Allos AI Platform) for pharmaceutical development that combines five integrated modules: Formulation Development, Scale-Up, Tech Transfer & QA, and Clinical Trials. The platform uses causal AI to simulate how interventions affect outcomes, enabling pharmaceutical companies to define robust operating windows before experiments run. The system delivers quantified improvements including 50% lower inter-patient variability and 70% fewer scale-up and tech transfer failures.

Product and service2 records
1Allos AI Platform
CategoryPharmaceutical R&D AI Software
Description

A causal AI platform that simulates how interventions affect outcomes in pharmaceutical development, defining robust operating windows before experiments run. The closed-loop system learns from every run and deviation, serving as a single source of truth with traceable drivers, documented assumptions, and controlled version history. Targeted at pharmaceutical sponsors developing specialty generics and complex small-molecule drugs for chronic conditions.

2Formulation Development Services
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Physics-based and AI-driven computational platform for drug discovery and materials science. Direct competitor in applying advanced modeling to pharmaceutical R&D, though broader in scope across discovery rather than formulation.

TypeDirect peer
Description

AI and robotics platform combining computation with experimental automation for drug discovery and crystalline formulation. Closely aligned to Allos on AI-led formulation and process optimization for pharma.

TypeDirect peer
Description

Provides modeling and simulation software for pharmaceutical formulation, PK/PD, and regulatory submissions. Highly comparable given the overlap on AI-driven formulation and scale-up workflows.

TypeDirect peer
Description

AI-driven drug discovery company combining high-throughput biology with machine learning. Comparable as a peer using AI/ML to compress pharmaceutical R&D cycles, though focused on novel therapeutics rather than formulation.

TypeDirect peer
Description

Machine learning-driven drug discovery platform combining computational biology with high-throughput experimental data. Comparable in applying AI/ML to improve pharma R&D success rates.

TypeDirect peer
Description

AI platform for small-molecule drug discovery using structure-based deep learning. Comparable in deploying AI for pharmaceutical development, particularly for small-molecule medicines targeted by Allos.

TypeBroad incumbent
Description

Established provider of model-informed drug development software and services spanning discovery, formulation, and regulatory. Overlaps with Allos on tech-transfer and CMC simulation but at significantly larger scale.

TypeBroad incumbent
Description

Cloud platform for life sciences R&D covering experiment tracking, molecular biology, and process development. Comparable as an informatics backbone for pharma R&D, though a broader platform than Allos's causal AI focus.

TypeBroad incumbent
Description

Scientific informatics platform for R&D data, workflows, and analytics across pharma and biotech. Comparable as an enabling informatics layer for pharmaceutical development teams.

TypeBroad incumbent
Description

Enterprise software for biopharma R&D workflows across discovery, development, and manufacturing. Comparable as an established informatics vendor competing for similar IT budgets in pharma R&D organizations.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Allos

Pharmaceutical R&D AI Softwareallos.ai

Allos AI is an Oxford University spinout selling a causal AI platform to pharmaceutical sponsors for formulation development, scale-up, tech transfer, and clinical trial optimization in specialty generics.

What Allos does

Allos AI is an Oxford University spinout that has built a causal AI platform targeted at pharmaceutical R&D, specifically formulation development for complex generics and small-molecule medicines for chronic conditions. The company's core technology combines causal inference with simulation-led Design of Experiments (DoE) and a closed-loop learning system to model cause-and-effect relationships between process interventions and outcomes before physical experiments are run. The platform is modularized into four product areas — Formulation Development, Scale-Up, Tech Transfer & QA, and Clinical Trials — each addressing a distinct phase of the molecule-to-validated-process workflow.

The product ingests structured experimental, process, and real-world data to perform phase-space mapping, identify robust operating windows, quantify sensitivities, and stratify patients. Disclosed validated outcomes include a 30% reduction in non-response rates to biologic therapies, 50% lower inter-patient variability, and 70% fewer scale-up and tech-transfer failures. The company positions its offering as the industry's first "glass-box" causal AI platform, contrasting its explainability with conventional black-box predictive models used in pharma R&D.

Commercially, Allos operates an enterprise direct-sales motion aimed at pharmaceutical sponsors, supported by a quote-based engagement model with no publicly disclosed pricing. Revenue mechanics span subscription/recurring AI platform services alongside professional services for formulation development. The company is headquartered in Oxford, United Kingdom, employs between 11 and 50 people, and was recently capitalized with a $5 million seed round led by Oxford Science Enterprises, with participation from Habico Invest (the family office of Danish pharma group Orifarm) and Berkeley SkyDeck. Note: a firmographic short description characterizes Allos as serving autoimmune prognosis/monitoring/treatment; the overwhelming majority of source material instead describes pharmaceutical formulation and R&D, which is the positioning used here.

Allos firmographics

Firmographics
Name
Allos
Legal name
Allos AI
Website
https://allos.ai
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
11–50 employees
Short description
Allos AI is an Oxford University spinout selling a causal AI platform to pharmaceutical sponsors for formulation development, scale-up, tech transfer, and clinical trial optimization in specialty generics.
Ownership category
akta.pro rank

Allos industry classification

Industry
Product category
Pharmaceutical R&D AI Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design and Related Services (54151)
SIC
Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731), Services-Computer Programming Services (7371)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Causal AI platform
  • Pharmaceutical R&D
  • Formulation development
  • Clinical trial optimization
  • Drug development AI

Where Allos is headquartered

Location

Headquarters

HQ city
Berkeley
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Allos business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. AI Platform Services: Providing causal AI platform services for formulation development, scale-up, tech transfer, QA, and clinical trials to pharmaceutical sponsors.
  2. Formulation Development Services: AI-powered formulation development services including phase-space mapping and simulation-led DoE for pharmaceutical companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Allos product offering

Product offering

Core offering

Allos develops and sells a Causal AI platform for pharmaceutical development that simulates how interventions affect outcomes, defining robust operating windows before experiments run. The platform combines integrated modules for formulation development, scale-up, tech transfer/QA, and clinical trials, learning from every run and deviation to serve as a single source of truth with traceable drivers. The company sells both the AI platform (subscription-based) and formulation development services to pharmaceutical sponsors.

Product overview

Allos offers a unified AI platform (Allos AI Platform) for pharmaceutical development that combines five integrated modules: Formulation Development, Scale-Up, Tech Transfer & QA, and Clinical Trials. The platform uses causal AI to simulate how interventions affect outcomes, enabling pharmaceutical companies to define robust operating windows before experiments run. The system delivers quantified improvements including 50% lower inter-patient variability and 70% fewer scale-up and tech transfer failures.

Differentiator

Problem solved

Functional benefit

Products and services

  • Allos AI Platform A causal AI platform that simulates how interventions affect outcomes in pharmaceutical development, defining robust operating windows before experiments run. The closed-loop system learns from every run and deviation, serving as a single source of truth with traceable drivers, documented assumptions, and controlled version history. Targeted at pharmaceutical sponsors developing specialty generics and complex small-molecule drugs for chronic conditions.
  • Formulation Development Services

Quantifiable outcome

  • 30% reduction in non-response rates to biologic therapies
  • +2 more outcomes

Companies that use Allos

Customer profile

Segments1 record

Ideal customer profiles1 record

Allos technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Allos partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Allos competitors and assessment

Company assessment

Direct peers

  • Schrödinger: Physics-based and AI-driven computational platform for drug discovery and materials science. Direct competitor in applying advanced modeling to pharmaceutical R&D, though broader in scope across discovery rather than formulation.
  • XtalPi: AI and robotics platform combining computation with experimental automation for drug discovery and crystalline formulation. Closely aligned to Allos on AI-led formulation and process optimization for pharma.
  • Simulations Plus: Provides modeling and simulation software for pharmaceutical formulation, PK/PD, and regulatory submissions. Highly comparable given the overlap on AI-driven formulation and scale-up workflows.
  • Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with machine learning. Comparable as a peer using AI/ML to compress pharmaceutical R&D cycles, though focused on novel therapeutics rather than formulation.
  • Insitro: Machine learning-driven drug discovery platform combining computational biology with high-throughput experimental data. Comparable in applying AI/ML to improve pharma R&D success rates.
  • Atomwise: AI platform for small-molecule drug discovery using structure-based deep learning. Comparable in deploying AI for pharmaceutical development, particularly for small-molecule medicines targeted by Allos.

Broad incumbents

  • Certara: Established provider of model-informed drug development software and services spanning discovery, formulation, and regulatory. Overlaps with Allos on tech-transfer and CMC simulation but at significantly larger scale.
  • Benchling: Cloud platform for life sciences R&D covering experiment tracking, molecular biology, and process development. Comparable as an informatics backbone for pharma R&D, though a broader platform than Allos's causal AI focus.
  • Dotmatics: Scientific informatics platform for R&D data, workflows, and analytics across pharma and biotech. Comparable as an enabling informatics layer for pharmaceutical development teams.
  • Genedata: Enterprise software for biopharma R&D workflows across discovery, development, and manufacturing. Comparable as an established informatics vendor competing for similar IT budgets in pharma R&D organizations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Allos social profiles

Digital presence

Allos financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Allos leadership team

Management profile

Number of profiles

Profiles1 record

Allos funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Allos M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Allos

What does Allos do?

Allos develops and sells a Causal AI platform for pharmaceutical development that simulates how interventions affect outcomes, defining robust operating windows before experiments run. The platform combines integrated modules for formulation development, scale-up, tech transfer/QA, and clinical trials, learning from every run and deviation to serve as a single source of truth with traceable drivers. The company sells both the AI platform (subscription-based) and formulation development services to pharmaceutical sponsors.

Is Allos a public or private company?

Allos is a private company. It is classified as venture growth investor backed and is currently operating.

When was Allos founded?

Allos was founded in 2024. It employs 11 to 50 people.

Where is Allos based?

Allos is headquartered in Berkeley, United States, in the North America region.

How does Allos make money?

Two revenue lines are on record. AI Platform Services are the primary driver. The others are formulation Development Services.

Who are Allos's main competitors?

Direct peers on record are Schrödinger, XtalPi, Simulations Plus, Recursion Pharmaceuticals, Insitro and Atomwise. Broad incumbents are Certara, Benchling, Dotmatics and Genedata.

Does Allos have an API?

No public API is recorded for Allos.

What industry is Allos in?

Allos's product category is Pharmaceutical R&D AI Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 541714 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
StartupHub.aiApplied Vertical AI: From Trading to Drug DiscoveryAyush Bhardwaj of Allos AI outlined a seven-step framework for developing applied vertical AI, emphasizing the critical role of proprietary data and domain expertise in creating competitive advantages. The process involves formulating narrow problems, identifying unique datasets, and maintaining a human-in-the-loop to refine models through iterative feedback. This approach aims to address data scarcity challenges in specialized sectors like finance and pharmaceuticals.MorningstarFFO ACCELERATES IN 2Q26 AND GROWS 12%ALLOS S.A. reported second-quarter 2026 results with FFO rising 12% to R$340.8 million, up from 2Q25. Net revenue grew 11.6% to R$732.3 million, driven by media and real estate development verticals. The company also saw sales up 4.6% and digital platform GMV increase 31%.DcatvciStart-up Allos AI Announces Seed Funding for AI-Enabled Pharma R&D, Formulation DevelopmentAllos AI, an Oxford University spinout incorporated in 2024, announced the closing of a $5 million seed funding round to advance its causal AI platform for pharmaceutical R&D and formulation development. The company applies causal AI to identify cause-and-effect relationships in drug development, aiming to reduce experimental cycles and improve clinical success rates, having demonstrated early validation including a 30% reduction in non-response rates to biologic therapies. Looking ahead, Allos AI plans to expand its capabilities across formulation design, clinical trial optimization, and real-world evidence generation while pursuing partnerships with pharmaceutical sponsors.Brazil JournalSegundo maior acionista da ALLOS vende 50% da posiçãoO grupo Alexander Otto, segundo maior acionista da ALLOS com 6,8% do capital, vendeu metade de sua posição através de um block trade,alienando 17,1 milhões de ações (3,4% do capital) por R$ 515 milhões, com preço de R$ 30 por ação e desconto de 3,47%. O grupo alemão, dono da maior rede de shoppings da Alemanha, decidiu manter o restante da posição e um assento no conselho para aproveitar o que considera potencial de valorização, já que a ALLOS negocia com desconto de cerca de 30% em relação à Multiplan e oferece dividend yield de 12,5%.MorningstarEBITDA GROWS 7.5% ACHIEVING A RECORD MARGIN OF 79%ALLOS S.A. announced its fourth quarter 2025 results, reporting EBITDA of R$672.0 million, a 7.5% increase year-over-year, with the company's EBITDA margin reaching a record 79.0%, up 192 basis points from the prior year period. The Brazilian mall operator also achieved record sales per square meter of R$2,524, a 5.1% increase in total sales compared to 4Q24, and grew its national market share to 20.9% in 2025. The company provided 2026 guidance projecting EBITDA between R$2,170 million and R$2,240 million, along with planned CAPEX of R$350-450 million and projected cash flow from mixed-use projects of R$539 million through 2036.SoapboxAllos AI raises £4m in a seed round led by Oxford Science Enterprises to reformulate complex small-molecule generic drugsAllos AI, a UK-based drug reformulation company, has raised £4 million in a seed funding round led by Oxford Science Enterprises, with participation from Habico Invest and the University of California accelerator Berkeley SKYDECK. The funding will support expansion of the company's formulation development and data science capabilities as it applies Causal AI to improve complex small-molecule generic drugs for better delivery and patient tolerability. The company aims to address the gap in post-market drug improvement by enabling more predictable, evidence-driven reformulation pathways that reduce development uncertainty and clinical burden.PR NewswireAllos Raises $5M to Apply Causal AI Across Complex Drug ReformulationAllos AI announced $5 million in seed financing led by Oxford Science Enterprises, with participation from Habico Invest, the family office of Danish pharmaceutical group Orifarm, and UC Berkeley accelerator SkyDeck, to commercialize the industry's first "glass-box" Causal AI platform for accelerating the reformulation of complex generic drugs. The funding will support expansion across formulation development and data science as the company targets hard-to-genericize small-molecule medicines for chronic conditions. The global specialty generics market is projected to grow from $77 billion in 2023 to $275 billion by 2032, highlighting the commercial opportunity in improving delivery, tolerability, and long-term outcomes of existing drugs.FinSMEsAllos Raises $5M in Seed FundingAllos, an Oxford, UK-based company applying causal AI to clinical outcomes and drug reformulation, has raised $5M in seed funding. The round was led by Oxford Science Enterprises with participation from Habico Invest and the University of California accelerator Berkeley SKYDECK. The company plans to use the proceeds to expand its formulation development and data science capabilities.